Keryx Biopharmaceuticals

NASDAQ: KERX
$3.36
-$0.07 (-2.0%)
Closing price December 12, 2018
The included Achaogen, Apple, Athenahealth, Crocs, Finisar, Jabil, Michael Kors, Occidental Petroleum, Starbucks and Walt Disney.
Walgreens, Starbucks, ICICI Bank, and Keryx Biopharmaceuticals all posted new 52-week lows Thursday.
Akebia Therapeutics and Keryx Biopharmaceuticals each saw their shares take a dive on Thursday following news that these two companies had agreed upon a merger.
Keryx Biopharmaceuticals shares took a hit on Tuesday after the company announced its third-quarter results and an update from the FDA.
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Last week, the Dow broke its six-day losing streak and S&P 500 hit a new record high. Despite all the positive sentiment in the market, quite a few companies still struggled.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Barrick Gold, Home Depot, Kroger, Newmont Mining and SolarCity.
Shares of Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) sank on Monday after the company announced that there will be an interruption in the supply of Auryxia (ferric citrate) tablets due to a...
A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as recent trading activity and the consensus price target.
September 8, 2015: Here are four stocks trading with heavy volume among 38 equities making new 52-week lows today. GoPro Inc.) dropped about 1.2% on Tuesday to post a new 52-week low of $36.38...
Monday's top analyst upgrades, downgrades and initiations include Citizens Financial, EOG Resources, Intuit, Keryx Biopharmaceuticals, Marathon Oil and Transocean.
May 4, 2015: Here are four stocks among the 36 equities making new 52-week lows today. Three of the four are repeats from yesterday’s list. PDL BioPharma Inc. (NASDAQ: PDLI) dropped 5% on Monday to...
The steep sell-off at the start of the week certainly enticed some insiders to step up to the plate and add to their positions.
With the 2014 trading year coming to an end last week, the pace of inside selling picked up a bit as insiders continued to sell stock in time to put it on the 2014 ledger and tax forms.
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep the answers short and...